{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:35:32Z","timestamp":1773693332609,"version":"3.50.1"},"reference-count":150,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY The prevalence of type 2 diabetes mellitus (T2DM) in the elderly grew sharply over the last decade. Reduced insulin sensitivity and secretory capacity, weight gain, sarcopenia, and elevated adiposity are all common metabolic and body changes in the aging population that favor an increased risk of hypoglycemia, frailty syndrome, falls, and cognitive dysfunction. First line antidiabetic therapy is frequently not safe in older individuals because of its high risk of hypoglycemia and prevalent co-morbid diseases, such as chronic kidney disease, osteoporosis, cardiovascular disease, and obesity. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new class of antidiabetic therapy that inhibits glucose and sodium reabsorption on renal proximal convoluted tubule. Its effect is well demonstrated in various clinical scenarios in the younger population. This review and metanalysis describe particularities of the SGLT2i on the elderly, with mechanistic insights of the potential benefit and remaining challenges about the use of these drugs in this important age group. Further, we will present a meta-analysis of the main effects of SGLT2i reported in post-hoc studies in which the median age of the subgroups analyzed was over 60 years. Despite the absence of specific clinical trials for this population, our findings suggest that SGLT2i therapy on older individuals is effective to lower glucose and maintain its effect on systolic blood pressure and body weight.<\/jats:p>","DOI":"10.1590\/1806-9282.65.1.70","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T13:20:58Z","timestamp":1549718458000},"page":"70-86","source":"Crossref","is-referenced-by-count":20,"title":["Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy"],"prefix":"10.1590","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-680X","authenticated-orcid":false,"given":"Riobaldo","family":"Cintra","sequence":"first","affiliation":[{"name":"Unicamp,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-1675","authenticated-orcid":false,"given":"Filipe A","family":"Moura","sequence":"additional","affiliation":[{"name":"Unicamp,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-356X","authenticated-orcid":false,"given":"Luis Sergio F de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Unicamp,  Brasil; State University of Campinas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-316X","authenticated-orcid":false,"given":"Joaquim","family":"Barreto","sequence":"additional","affiliation":[{"name":"Unicamp,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-6902","authenticated-orcid":false,"given":"Marcos","family":"Tambascia","sequence":"additional","affiliation":[{"name":"State University of Campinas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-6710","authenticated-orcid":false,"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-2052","authenticated-orcid":false,"given":"Andrei C.","family":"Sposito","sequence":"additional","affiliation":[{"name":"Unicamp,  Brasil; State University of Campinas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019,1]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.mcna.2011.02.003","article-title":"Diabetes and insulin resistance in older people","volume":"95","author":"Viljoen A","year":"2011","journal-title":"Med Clin North Am"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11892-013-0425-5","article-title":"Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden","volume":"13","author":"Corriere M","year":"2013","journal-title":"Curr Diab Rep"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/archinternmed.2007.35","article-title":"The growing burden of diabetes mellitus in the US elderly population","volume":"168","author":"Sloan FA","year":"2008","journal-title":"Arch Intern Med"},{"issue":"14","key":"ref4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth GA","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(14)70176-7","article-title":"Diabetes in older people: new insights and remaining challenges","volume":"3","author":"Sinclair A","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1210\/jc.2011-1798","article-title":"Ectopic lipid accumulation and reduced glucose tolerance in elderly adults are accompanied by altered skeletal muscle mitochondrial activity","volume":"97","author":"Johannsen DL","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1463-1326.2011.01443.x","article-title":"Longevity of human islet alpha- and beta-cells","volume":"13","author":"Cnop M","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/320482","article-title":"Pancreatic function, type 2 diabetes, and metabolism in aging","volume":"2012","author":"Gong Z","year":"2012","journal-title":"Int J Endocrinol"},{"issue":"12","key":"ref9","first-page":"4088","article-title":"Increased disorderliness of basal insulin release, attenuated insulin secretory burst mass, and reduced ultradian rhythmicity of insulin secretion in older individuals","volume":"82","author":"Meneilly GS","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/dc09-0267","article-title":"Physical inactivity and obesity underlie the insulin resistance of aging","volume":"32","author":"Amati F","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0026-0495(03)00100-8","article-title":"Age or waist as determinant of insulin action?","volume":"52","author":"Bryhni B","year":"2003","journal-title":"Metabolism"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo RA","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo RA","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci A","year":"2014","journal-title":"J Clin Invest"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu WT","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini E","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","volume":"17","author":"Bode B","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"ref18","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen I","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett AH","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder J","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dom.12543","article-title":"Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes","volume":"17","author":"Matthaei S","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan DE","year":"2014","journal-title":"Kidney Int"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter LA","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal B","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale JF","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-14-37","article-title":"Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","volume":"14","author":"Sinclair A","year":"2014","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode B","year":"2013","journal-title":"Hosp Pract"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","journal-title":"PLoS Med"},{"key":"ref30","first-page":"1963","article-title":"Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options","volume":"9","author":"Du YF","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/archinternmed.2010.539","article-title":"Frequent hypoglycemia among elderly patients with poor glycemic control","volume":"171","author":"Munshi MN","year":"2011","journal-title":"Arch Intern Med"},{"issue":"2","key":"ref32","first-page":"e32","article-title":"Non-severe hypoglycemia risk difference between sulfonylurea and sodium-glucose cotransporter-2 inhibitors (SGLT2-I) as an add-on to metformin in randomized controlled trials","volume":"24","author":"Farahani P","year":"2017","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0047-6374(90)90130-8","article-title":"Changes in metabolite transport by small intestine and kidney of young and old rats","volume":"52","author":"Treves C","year":"1990","journal-title":"Mech Ageing Dev"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-015-0591-y","article-title":"Update on blood pressure goals in diabetes mellitus","volume":"17","author":"Laffin LJ","year":"2015","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jash.2014.11.001","article-title":"SGLT2 inhibitors: their potential reduction in blood pressure","volume":"9","author":"Maliha G","year":"2015","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/M13-2981","article-title":"Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view","volume":"160","author":"Wright Jr JT","year":"2014","journal-title":"Ann Intern Med"},{"issue":"20","key":"ref37","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","article-title":"ACCF\/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension","volume":"57","author":"Aronow WS","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","article-title":"Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications","volume":"77","author":"Palombo C","year":"2016","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcdb.2011.02.013","article-title":"Glyoxalase in ageing","volume":"22","author":"Xue M","year":"2011","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2007.10.047","article-title":"Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness","volume":"132","author":"Choi KM","year":"2009","journal-title":"Int J Cardiol"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123903","article-title":"Modifiable risk factors for increased arterial stiffness in outpatient nephrology","volume":"10","author":"Elewa U","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton R","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney DZ","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze M","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/dom.12589","article-title":"Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes","volume":"18","author":"Fulcher G","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"ref46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink HJ","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1524-6175.2001.00903.x","article-title":"Hypertension in the elderly: a review of the importance of systolic blood pressure elevation","volume":"4","author":"Basile J","year":"2002","journal-title":"J Clin Hypertens"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber MA","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha S","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"ref50","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008274.pub2","article-title":"Long-term effects of weight-reducing diets in hypertensive patients","author":"Siebenhofer A","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"ref51","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/dom.12500","article-title":"Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels","volume":"17","author":"Sjostrom CD","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"9882","key":"ref52","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0140-6736(13)61203-9","article-title":"Frailty assessment in elderly people","volume":"381","author":"Iqbal J","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"ref53","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/jgs.13608","article-title":"Loss of weight in obese older adults: a biomarker of impending expansion of multimorbidity?","volume":"63","author":"Fabbri E","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1046\/j.1532-5415.2001.49258.x","article-title":"Weight change in old age and its association with mortality","volume":"49","author":"Newman AB","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3945\/ajcn.110.006379","article-title":"The effect of intentional weight loss on all-cause mortality in older adults: results of a randomized controlled weight-loss trial","volume":"94","author":"Shea MK","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/gerona\/glu005","article-title":"Attribution of causes of weight loss and weight gain to 3-year mortality in older adults: results from the Longitudinal Aging Study Amsterdam","volume":"69","author":"Wijnhoven HA","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"24","key":"ref57","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.1995.03530240025035","article-title":"Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial","volume":"274","author":"Katzel LI","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"ref58","first-page":"977","article-title":"Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men","volume":"85","author":"Purnell JQ","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1152\/jappl.1996.81.1.318","article-title":"Distinct effects of aerobic exercise training and weight loss on glucose homeostasis in obese sedentary men","volume":"81","author":"Dengel DR","year":"1996","journal-title":"J Appl Physiol"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/gerona\/gls092","article-title":"Fat mass loss predicts gain in physical function with intentional weight loss in older adults","volume":"68","author":"Beavers KM","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"ref61","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1532-5415.2004.52261.x","article-title":"Determinants of lower-body muscle power in early postmenopausal women","volume":"52","author":"Sipila S","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"ref62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1475-097X.1994.tb00402.x","article-title":"Knee extension strength and walking speed in relation to quadriceps muscle composition and training in elderly women","volume":"14","author":"Sipila S","year":"1994","journal-title":"Clin Physiol"},{"issue":"6","key":"ref63","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1152\/jappl.2001.90.6.2157","article-title":"Attenuation of skeletal muscle and strength in the elderly: the Health ABC Study","volume":"90","author":"Goodpaster BH","year":"2001","journal-title":"J Appl Physiol"},{"issue":"5","key":"ref64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1532-5415.2002.50217.x","article-title":"Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study","volume":"50","author":"Visser M","year":"2002","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/gerona\/61.1.72","article-title":"Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort","volume":"61","author":"Newman AB","year":"2006","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"ref66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/gerona\/60.3.324","article-title":"Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons","volume":"60","author":"Visser M","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9","key":"ref67","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1210\/jc.2013-3200","article-title":"Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults","volume":"99","author":"Aguirre L","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pcad.2014.01.001","article-title":"Low weight and overweightness in older adults: risk and clinical management","volume":"57","author":"Jahangir E","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","article-title":"Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial","volume":"38","author":"Matthaei S","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13300-015-0117-z","article-title":"Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial","volume":"6","author":"Fulcher G","year":"2015","journal-title":"Diabetes Ther"},{"issue":"9","key":"ref71","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini G","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"ref72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150756","article-title":"Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice","volume":"11","author":"Chiba Y","year":"2016","journal-title":"PloS One"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato S","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.2337\/dc11-1032","article-title":"Insulin sensitizers may attenuate lean mass loss in older men with diabetes","volume":"34","author":"Lee CG","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"ref75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jama.2015.6753","article-title":"Chronic kidney disease in older people","volume":"314","author":"Levey AS","year":"2015","journal-title":"JAMA"},{"issue":"7577","key":"ref76","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.39001.657755.BE","article-title":"Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey","volume":"333","author":"Hallan SI","year":"2006","journal-title":"BMJ"},{"issue":"4","key":"ref77","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"64","author":"Tuttle KR","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"ref78","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan SI","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"ref79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and functional changes with the aging kidney","volume":"23","author":"Denic A","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"ref80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0006-291X(02)00818-5","article-title":"High glucose-induced replicative senescence: point of no return and effect of telomerase","volume":"296","author":"Blazer S","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"ref81","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2337\/db05-1607","article-title":"Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by high glucose in endothelial cells","volume":"55","author":"Yokoi T","year":"2006","journal-title":"Diabetes"},{"issue":"5","key":"ref82","doi-asserted-by":"crossref","first-page":"F1563","DOI":"10.1152\/ajprenal.90302.2008","article-title":"Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy","volume":"295","author":"Verzola D","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"ref83","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jdiacomp.2014.05.010","article-title":"Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy","volume":"28","author":"Kitada K","year":"2014","journal-title":"J Diabetes Complications"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","article-title":"Sodium\/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes","volume":"64","author":"De Nicola L","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"ref85","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/dom.12630","article-title":"Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?","volume":"18","author":"Gallagher H","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"ref86","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas HS","year":"2008","journal-title":"Endocrinology"},{"issue":"12","key":"ref87","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune H","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"ref88","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"ref89","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"Skrtic M","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"ref90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2133\/dmpk.19.41","article-title":"Decreased expression of glucose and peptide transporters in rat remnant kidney","volume":"19","author":"Nakamura N","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"ref91","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12058","article-title":"SGLT2 inhibitors act from the extracellular surface of the cell membrane","volume":"2","author":"Ghezzi C","year":"2014","journal-title":"Physiol Rep"},{"issue":"2","key":"ref92","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","volume":"17","author":"Sha S","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"ref93","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrneph.2015.114","article-title":"Management of hypertension in chronic kidney disease","volume":"11","author":"Townsend RR","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"9982","key":"ref94","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer SC","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"ref95","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2215\/CJN.02250409","article-title":"Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan SD","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"ref96","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1185\/03007995.2015.1092128","article-title":"Renal effects of canagliflozin in type 2 diabetes mellitus","volume":"31","author":"Perkovic V","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"ref97","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney DZ","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"ref98","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40620-016-0261-1","article-title":"The effect of dapagliflozin on renal function in patients with type 2 diabetes","volume":"29","author":"Kohan DE","year":"2016","journal-title":"J Nephrol"},{"issue":"5","key":"ref99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale JF","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"ref100","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding JP","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"ref101","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List JF","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"ref102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/157016110790886947","article-title":"Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus","volume":"8","author":"Hayashi T","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"ref103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout H","year":"2014","journal-title":"Am J Nephrol"},{"issue":"5","key":"ref104","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni D","year":"2014","journal-title":"Clin Ther"},{"issue":"9","key":"ref105","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu N","year":"2015","journal-title":"Diabetes Care"},{"key":"ref106","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-13-65","article-title":"Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study","volume":"13","author":"Kaku K","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"ref107","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pareatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner C","year":"2015","journal-title":"Nat Med"},{"issue":"8","key":"ref108","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"Perspective: SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor SI","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"ref109","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","journal-title":"Diabetes Care"},{"issue":"9922","key":"ref110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","article-title":"The many faces of diabetes: a disease with increasing heterogeneity","volume":"383","author":"Tuomi T","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"ref111","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000356747","article-title":"Autoimmune aspects of type 2 diabetes mellitus: a mini-review","volume":"60","author":"Itariu BK","year":"2014","journal-title":"Gerontology"},{"issue":"2","key":"ref112","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth W","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"ref113","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/dom.12031","article-title":"Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs","volume":"15","author":"Signorovitch JE","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"ref114","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1463-1326.2012.01583.x","article-title":"Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes","volume":"14","author":"Johnston SS","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"ref115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/dc13-1384","article-title":"Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study","volume":"37","author":"Feinkohl I","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"ref116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.12587","article-title":"Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose lowering agents: systematic review and meta-analysis","volume":"18","author":"Mattishent K","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"ref117","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamainternmed.2013.6189","article-title":"Glucose control in older adults with diabetes mellitus: more harm than good?","volume":"173","author":"Lipska KJ","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ref118","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jdiacomp.2012.06.008","article-title":"Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)","volume":"26","author":"Hirji I","year":"2012","journal-title":"J Diabetes Complications"},{"issue":"3","key":"ref119","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings S","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"ref120","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson KM","year":"2013","journal-title":"J Diabetes Complications"},{"issue":"10","key":"ref121","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos A","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"ref122","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","article-title":"Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","volume":"30","author":"Nyirjesy P","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"ref123","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/820615","article-title":"Osteoporosis, fractures, and diabetes","volume":"2014","author":"Jackuliak P","year":"2014","journal-title":"Int J Endocrinol"},{"issue":"14","key":"ref124","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archinte.165.14.1612","article-title":"Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study","volume":"165","author":"Strotmeyer ES","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","article-title":"SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice","volume":"82","author":"Thrailkill KM","year":"2016","journal-title":"Bone"},{"issue":"11","key":"ref126","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren O","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"ref127","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian JP","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"ref128","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/03007995.2016.1174841","article-title":"The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus","volume":"32","author":"Alba M","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"ref129","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00198-015-3123-0","article-title":"Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review","volume":"26","author":"Palermo A","year":"2015","journal-title":"Osteoporos Int"},{"issue":"4","key":"ref130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis","volume":"18","author":"Vestergaard P","year":"2007","journal-title":"Osteoporos Int"},{"issue":"1","key":"ref131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts NB","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"ref132","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu JH","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9607","key":"ref133","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney PM","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"ref134","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2014.08.037","article-title":"Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study","volume":"237","author":"Brandenburg VM","year":"2014","journal-title":"Atherosclerosis"},{"issue":"6","key":"ref135","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/jcmm.12813","article-title":"Renalase attenuates hypertension, renal injury and cardiac remodelling in rats with subtotal nephrectomy","volume":"20","author":"Yin J","year":"2016","journal-title":"J Cell Mol Med"},{"issue":"3","key":"ref136","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00125-005-0091-5","article-title":"Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db\/db mice","volume":"49","author":"Anzawa R","year":"2006","journal-title":"Diabetologia"},{"issue":"3","key":"ref137","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrcardio.2012.201","article-title":"Causes and prevention of sudden cardiac death in the elderly","volume":"10","author":"Tung P","year":"2013","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"ref138","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2459\/01.JCM.0000237904.95882.c8","article-title":"Dysrhythmia and electrocardiographic changes in diabetes mellitus: pathophysiology and impact on the incidence of sudden cardiac death","volume":"7","author":"El-Menyar AA","year":"2006","journal-title":"J Cardiovasc Med"},{"issue":"1","key":"ref139","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee SK","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"3","key":"ref140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen AJ","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"ref141","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar S","year":"2016","journal-title":"Diabetes Care"},{"issue":"14","key":"ref142","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0002-9149(99)80304-X","article-title":"Breath acetone in congestive heart failure","volume":"76","author":"Kupari M","year":"1995","journal-title":"Am J Cardiol"},{"issue":"4","key":"ref143","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCULATIONAHA.107.702795","article-title":"Metabolic mechanisms in heart failure","volume":"116","author":"Ashrafian H","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"ref144","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/BF00788500","article-title":"Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration","volume":"90","author":"Jeffrey FM","year":"1995","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"ref145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12603-009-0026-9","article-title":"Metabolic response to a ketogenic breakfast in the healthy elderly","volume":"13","author":"Freemantle E","year":"2009","journal-title":"J Nutr Health Aging"},{"issue":"14","key":"ref146","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan WN","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"ref147","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin CA","year":"2015","journal-title":"JAMA"},{"issue":"25","key":"ref148","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/eurheartj\/ehv093","article-title":"Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies","volume":"36","author":"Ricci F","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"ref149","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/clinchem\/37.10.1820","article-title":"Abnormal sodium metabolism and plasma renin activity (renal renin secretion) and the vasoconstriction volume hypothesis: implications for pathogenesis and treatment of hypertension and its vascular consequences (heart attack, stroke)","volume":"37","author":"Laragh JH","year":"1991","journal-title":"Clin Chem"},{"issue":"7","key":"ref150","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/HJH.0b013e3282fe1d55","article-title":"Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested case-control study","volume":"26","author":"Mollsten A","year":"2008","journal-title":"J Hypertens"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v65n1\/1806-9282-ramb-65-1-0070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T13:12:09Z","timestamp":1579871529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302019000100070&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["S0104-42302019000100070"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.65.1.70","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}